Mpox Vaccine Production Reaches 10 Million Doses

Bavarian Nordic A/S (OMX: BAVA) announced today it's interim financial results and business progress for the third quarter of 2024, highlighting mpox vaccine sales.

Bavarian Nordic stated on November 15, 2024, that it retains sufficient capacity to fulfill the requirement as stated by Africa CDC for at least 10 million doses of MVA-BN® (JYNNEOS®) by the end of 2025 and could even further scale up capacity for future demand if needed.

For 2025, the Company has so far secured revenue from mpox/smallpox vaccine orders of approximately DKK 2,400 million.

Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said in a press release, “We have had a busy but highly purposeful and rewarding third quarter, where we have worked intensively to support the efforts to curb the ongoing mpox outbreak in Africa."

In the United States, the government recommends two doses of JYNNEOS to provide more robust protection. However, routine immunization against mpox is not recommended for the general public. The U.S. CDC does not endorse booster doses (3rd).